Appointed
Akintunde Bello
Class II director
XLO ·
Xilio Therapeutics, Inc.
elected Akintunde Bello, Ph.D., as a Class II director of the Company
Ready 8-Ks
50
Latest filing
June 12, 2026, 4:05 PM ET
Top materiality
0.85
Event mix
other_material ×24 · earnings ×11 · leadership ×6
Sentiment
16 pos · 5 neg · 29 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for XLO
Highest-materiality recent filing
Xilio reports 40% ORR in MSS mCRC with high plasma TMB; advances masked T cell engager programs
- Vilastobart + atezolizumab: 40% ORR in heavily pre-treated MSS mCRC without liver mets and high plasma TMB (≥10 mut/Mb); p=0.05 correlation.
- Estimated 55% of MSS CRC patients have high plasma TMB via Guardant360 assay, vs <10% by tissue TMB.
-
Xilio Q1 net loss $9.5M; cash $150.3M; XTX501 IND planned mid-2026
Cash and cash equivalents $150.3M at Mar 31, 2026 (vs $137.5M Dec 31, 2025); runway into early 2028.
-
Xilio announces Q4 net income $10.4M, cash $137.5M, runway through 2027
Net income of $10.4M in Q4 2025 vs net loss of $13.1M in Q4 2024; full year net loss narrowed to $35.0M from $58.2M.
-
Xilio Therapeutics prices $40M pre-funded warrant offering; lead investor Coastlands Capital
Pre-funded warrants to purchase 74,780,300 common shares at $0.5349/warrant; exercise price $0.0001/share.
-
Xilio reports 48.2M Series B warrants exercised for $35.8M, cash runway into Q2 2027
48.2M Series B warrants exercised by Dec 31, 2025, yielding $35.8M gross proceeds; issued 8.2M shares and 40M prefunded warrants.
-
Xilio Q3 net loss $16.3M; cash $103.8M; vilastobart 40% ORR in MSS mCRC subset
Net loss $16.3M for Q3 2025 vs $14.0M in Q3 2024; collaboration revenue $19.1M (up from $2.3M YoY).
-
Xilio reports 40% ORR in MSS mCRC with high plasma TMB; advances masked T cell engager programs
Vilastobart + atezolizumab: 40% ORR in heavily pre-treated MSS mCRC without liver mets and high plasma TMB (≥10 mut/Mb); p=0.05 correlation.
-
Xilio Therapeutics transfers to Nasdaq Capital Market; extended bid price deadline to March 2026
Company received approval on Oct 2, 2025 to transfer listing from Nasdaq Global Select to Capital Market, effective Oct 6.
-
Xilio starts Phase 2 XTX301 (IL-12), gets $17.5M milestone from Gilead; cash extended to Q1 2027
Initiated patient dosing in Phase 2 of efarindodekin alfa (XTX301) for advanced solid tumors; RP2D selected.
-
Reported stockholders' equity of $7.069M as of June 30, 2025, below $10M minimum required for Nasdaq Global Select Market.
-
Xilio Therapeutics prices $50M public offering of warrants; cash runway through Q3 2026
Net proceeds of ~$46.6M from offering of pre-funded warrants and Series A/B/C warrants, priced at $0.7499 per unit.
-
Xilio reports 26% ORR for vilastobart+atezo in MSS CRC without liver mets; plans to partner program
26% ORR (7 PRs, 6 confirmed) in 27 MSS CRC patients without liver metastases; responses ongoing up to 37 weeks.
-
Xilio reports Q1 net loss $13.3M, cash $89.1M; AbbVie deal provides $52M upfront
Net loss $13.3M for Q1 2025, vs $17.2M Q1 2024.
-
Xilio receives Nasdaq bid-price deficiency letter for shares below $1.00
Notice dated April 4, 2025; stock closed below $1.00 for 30 consecutive business days.
-
Xilio reports Q4/FY 2024 results; cash $55.3M, AbbVie collaboration adds $52M upfront
Net loss of $13.1M in Q4 2024, $58.2M for FY 2024; license revenue $6.3M from Gilead deal.
-
Xilio signs AbbVie deal: $52M upfront, up to $2.1B milestones for masked T-cell engagers
Upfront $52M ($42M cash + $10M equity at $2.30/shr); AbbVie gets options for 4 masked TCE programs and license for masked antibody.
-
Xilio reports 27% response rate for vilastobart + atezolizumab in MSS CRC Phase 2 trial
27% preliminary ORR (3 PRs, 2 confirmed) in MSS CRC patients without liver metastases as of Jan 13, 2025 cutoff.
-
Xilio completes $25M Gilead investment; XTX301 shows no DLTs in Phase 1; cash into Q3 2025
Completed $8.2M Gilead private placement (common + prefunded warrants), exhausting $25M stock purchase agreement.
-
Xilio Q3 net loss $14.0M; Phase 1C vilastobart + atezolizumab shows partial responses in cold tumors
Cash $61.3M as of Sept 30, 2024; cash runway through Q2 2025.
-
Xilio Therapeutics receives Nasdaq deficiency notice for bid price below $1.00 per share
Received Nasdaq notice on Sept 10, 2024; common stock bid price below $1.00 for 30 consecutive business days.
-
Xilio Q2 net loss $13.9M; initiates Phase 2 for XTX101 in MSS CRC
Net loss $13.9M in Q2 2024 vs $19.4M in Q2 2023; R&D expenses $11.2M.
-
Xilio Q1 net loss $17.2M; Gilead deal funds cash runway into Q2 2025
Net loss $17.2M in Q1 2024 vs $22.6M YoY; cash and equivalents $34.0M at March 31.
-
Xilio reports FY2023 net loss of $76.4M, Gilead licenses XTX301 for up to $604M
Cash and cash equivalents were $44.7M at Dec 31, 2023, down from $120.4M a year earlier.
-
Exclusive global license to Gilead for tumor-activated IL-12 XTX301; Xilio receives $43.5M upfront (cash + equity), potential $604M milestones and tiered royalties.
-
Xilio Therapeutics issues 6.86M shares to Gilead at $1.97/share for $13.5M private placement
Closed private placement of 6,860,223 shares to Gilead Sciences at $1.97/share for ~$13.5M.
-
Xilio receives Nasdaq deficiency notice for bid price below $1.00/share
Bid price closed below $1.00 for 30 consecutive business days; violates Minimum Bid Requirement.
-
Initiated enrollment for Phase 1 dose escalation of XTX101 in combination with atezolizumab; RP2D for combo expected Q2 2024.
-
Xilio reports Q3 net loss of $16.7M; cash runway into Q2 2024; XTX202 shows 50% DCR at ≥2.8 mg/kg
Net loss $16.7M vs $19.8M YoY; R&D spend $11.1M, G&A $6.3M.
-
Xilio reports XTX202 Phase 1/2 data: 50% disease control at ≥2.8 mg/kg, no vascular leak syndrome
62 patients dosed; 42 evaluable for activity: 31% disease control rate (13 SD ≥9 wks) across all doses, 50% at ≥2.8 mg/kg (3/6).
-
Xilio Therapeutics announces Roche collaboration for XTX101 in MSS CRC; cash $75.4M
Entered clinical trial collaboration with Roche; Xilio retains rights to XTX101; eligible for cost-sharing payments.
-
Preliminary data from Phase 1 trial of XTX101 in 25 patients with advanced solid tumors; RP2D set at 150 mg Q6W.
-
Xilio reports Q1 net loss $22.6M; initiates Phase 2 trial for XTX202
Cash and cash equivalents $93.3M as of Mar 31, 2023; runway into Q2 2024.
-
Xilio reports FY2022 net loss $88.2M; cash $120.4M; XTX202 shows early tumor-selective activation
Cash and cash equivalents $120.4M as of Dec 31, 2022, down from $198.1M; cash runway into Q2 2024.
Executive changes
Appointed
James Shannon
Class I Director
XLO ·
Xilio Therapeutics, Inc.
elected James Shannon, M.D., as a Class I director of the Company
Role change
René Russo
President
XLO ·
Xilio Therapeutics, Inc.
Effective September 8, 2023, the board of directors (the “Board”) of the Company appointed René Russo, Pharm.D., 48, to President of the Company.
Departed
Martin Huber
President and Head of Research and Development
XLO ·
Xilio Therapeutics, Inc.
Martin Huber, M.D., notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as President and Head of Research and Development of the Company, effective September 8, 2023, to pursue other opportunities.
Role change
Christopher Frankenfield
Chief Operating Officer
XLO ·
Xilio Therapeutics, Inc.
On August 3, 2023, the board of directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Christopher Frankenfield, the Company’s Chief Legal and Administrative Officer, to the position of Chief Operating Officer, effective immediately.
Appointed
Kevin Brennan
Senior Vice President, Finance and Accounting
XLO ·
Xilio Therapeutics, Inc.
On March 30, 2023, Kevin Brennan joined Xilio Therapeutics, Inc. (the “Company”) as Senior Vice President, Finance and Accounting, and the board of directors (the “Board”) of the Company appointed Mr. Brennan to serve as the Company’s principal financial officer and principal accounting officer.
Departed
Edward C. English
vice president, finance, accounting and treasury and principal accounting officer
XLO ·
Xilio Therapeutics, Inc.
On December 19, 2022, Edward C. English notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as vice president, finance, accounting and treasury and principal accounting officer of the Company, effective January 31, 2023, to pursue other opportunities.
Appointed
Tomas Heyman
Class I director
XLO ·
Xilio Therapeutics, Inc.
Effective September 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tomas Heyman to the Board as a Class I director of the Company, to serve in such capacity until the Company’s 2025 annual meeting of stockholders or until his earlier resignation, death, or removal.
Departed
Salvatore Giovine
chief financial officer
XLO ·
Xilio Therapeutics, Inc.
On July 25, 2022, Salvatore Giovine notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer (principal financial officer) of the Company, effective August 19, 2022, for personal family reasons.
Appointed
Robert Ross
Class II director
XLO ·
Xilio Therapeutics, Inc.
Effective June 15, 2022, the Board, on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Ross, M.D. to the Board as a Class II director of the Company
Role change
Martin Huber
President
XLO ·
Xilio Therapeutics, Inc.
On June 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Martin Huber, M.D., 62, to President of the Company.
Departed
Rachel Humphrey
director
XLO ·
Xilio Therapeutics, Inc.
On February 3, 2022, Rachel Humphrey, M.D. notified Xilio Therapeutics, Inc. (the “Company”) of her decision to resign from the board of directors of the Company effective as of such date.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material